Jubilant Ingrevia Limited — Investor Meet, 27-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Ingrevia kicked off FY27 strongly. Revenue soared 25% YoY to INR1,300 crore, EBITDA jumped 36% to INR209 crore, and PAT increased 41% to INR106 crore. Growth was driven by Specialty Chemicals and Nutrition, plus a Chemical Intermediates rebound. The company holds its FY27 EBITDA outlook at INR750-800 crore, projecting sequential gains. Their CDMO/Fine Chemicals pipeline is robust with 25+ confirmed molecules. A large agro CDMO contract saw temporary Q1 volume adjustments but is fully protected; Q2 volumes are set to rise. Management expresses confidence in strategic growth and margin protection.